Last reviewed · How we verify
SARS-CoV-2 rS antigen/Matrix-M Adjuvant
This vaccine delivers the SARS-CoV-2 spike protein antigen with Matrix-M adjuvant to stimulate immune responses against COVID-19.
This vaccine delivers the SARS-CoV-2 spike protein antigen with Matrix-M adjuvant to stimulate immune responses against COVID-19. Used for COVID-19 prevention in adults, COVID-19 prevention in adolescents (age 12+).
At a glance
| Generic name | SARS-CoV-2 rS antigen/Matrix-M Adjuvant |
|---|---|
| Also known as | Updated Novavax COVID-19 vaccine |
| Sponsor | Novavax |
| Drug class | Recombinant protein vaccine with adjuvant |
| Target | SARS-CoV-2 spike protein |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains a recombinant SARS-CoV-2 spike (S) protein antigen produced in insect cells, combined with Matrix-M, a saponin-based adjuvant that enhances innate immune activation and adaptive immune responses. This combination promotes both antibody production and T-cell mediated immunity to protect against SARS-CoV-2 infection and COVID-19 disease.
Approved indications
- COVID-19 prevention in adults
- COVID-19 prevention in adolescents (age 12+)
Common side effects
- Injection site pain
- Fatigue
- Myalgia
- Headache
- Fever
- Nausea
Key clinical trials
- A Strain Change Study for SARS-CoV-2 rS Vaccines (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine (PHASE3)
- Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines (PHASE3)
- Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines (PHASE3)
- Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines (PHASE1, PHASE2)
- Lot Consistency Study of COVID-19 and Influenza Combination Vaccine (PHASE2, PHASE3)
- Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines (PHASE2, PHASE3)
- Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SARS-CoV-2 rS antigen/Matrix-M Adjuvant CI brief — competitive landscape report
- SARS-CoV-2 rS antigen/Matrix-M Adjuvant updates RSS · CI watch RSS
- Novavax portfolio CI